Decreased levels of advanced glycation end-products in patients with Gilbert syndrome.

Levels of both AGEs remained substantially lower in GS compared to normobilirubinemic controls even after adjustment for selected vascular risk and other modifying factors, in support of previous data on antioxidant properties of bilirUBin.